AKT1 and B-cell chronic lymphocytic leukemia: The sIgM levels may indirectly inform the degree of AKT activation and, while clinical trial data are maturing with longer follow-ups, it may be possible that different combinations including PI3K/AKT inhibitors may need renewed consideration in CLL with high sIgM.